Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways

ÇAVDAR Z., URAL ÖZKAN C., Kocak A., ARSLAN Ş., Ersan S., ÖZBAL S., ...Daha Fazla

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, sa.4, ss.452-461, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1515/tjb-2018-0155
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.452-461
  • Anahtar Kelimeler: Paricalcitol, Ischemia, Kidney, p38 MAPK, PI3K/Akt, ISCHEMIA-REPERFUSION INJURY, INDUCED KIDNEY INJURY, NF-KAPPA-B, ISCHAEMIA/REPERFUSION INJURY, INFLAMMATION, ERYTHROPOIETIN, APOPTOSIS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: This study aimed to investigate the renoprotective effects of paricalcitol, a synhetic vitamin D analog, through its possible roles on p38 MAPK and PI3K/Akt signaling pathways to prevent oxidative stress, inflammation and apoptosis during renal I/R.